Gossamer Bio Gains Buy Ratings with $9–$10 Price Targets and Trial Milestones
H.C. Wainwright reiterated a Buy rating on Gossamer Bio with a $10 price target, following Barclays’ Overweight initiation at $9. Cantor Fitzgerald also maintains an Overweight stance and highlights mid-to-late February seralutinib trial readouts with imaging data due in Q2 2026.
1. Analyst Ratings and Price Targets
H.C. Wainwright analyst Patrick Trucchio reaffirmed a Buy rating on Gossamer Bio, assigning a $10 price target after Barclays initiated coverage with an Overweight rating and $9 target. Cantor Fitzgerald’s Overweight rating was also reiterated, reflecting a consensus view that the stock is undervalued relative to peers.
2. Upcoming Clinical Readouts
Cantor Fitzgerald forecasts topline results from the Phase II seralutinib trial in pulmonary arterial hypertension in mid to late February 2026. The firm also anticipates presentation of imaging data for the same program in the second quarter of 2026, which could catalyze stock movement.
3. Valuation and M&A Potential
Barclays cited healthy biotech fundamentals and anticipated industry consolidation as drivers for valuation upside. Analysts believe Gossamer Bio’s focus on immunology, inflammation and oncology pipelines positions it to benefit from potential mergers and acquisitions in 2026.